Associated Papers
HIP1-ALK-Rearranged Lung Cancer in a Young Adult With BRAF V600E Mutation Detected After ALK Tyrosine Kinase Inhibitor Therapy: A Case Report.
Ogimoto A et al.
Jto Clinical and Research Reports, 2024
Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
Kang J et al.
Genes, Chromosomes & Cancer, 2022
Association of anaplastic lymphoma kinase variants and alterations with ensartinib response duration in non-small cell lung cancer.
Hou D et al.
Thoracic Cancer, 2021
34288491 (PubMed )
Supplement: TCA-12-2388-s001.docx
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer.
Horn L et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2019
Insight into drug resistance mechanisms and discovery of potential inhibitors against wild-type and L1196M mutant ALK from FDA-approved drugs.
Li J et al.
Journal of Molecular Modeling, 2016
Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature.
van der Wekken AJ et al.
Critical Reviews in Oncology/hematology, 2016
Select a paper to view details